

DAFTAR PUSTAKA

1. Putranto TA. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis. Vol. 16, Pedoman Nasional. Kementerian Kesehatan Republik Indonesia; 2020. 132.
2. Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. *Major Infectious Diseases*. 3rd ed. Washington (DC); 2017 Nov 3. Chapter 11. doi:10.1596/978-1-4648-0524-0_ch11.
3. World Health Organization. *Tuberculosis* [Internet]. 2025 Mar 14 [cited 2025 Aug 13]. Available from: World Health Organization fact sheet on tuberculosis.
4. World Health Organization. *Global tuberculosis report 2023* [Internet]. Geneva: World Health Organization; 2023.
5. Kemenkes RI. Cegah dan Obati TB dengan Terapi Pencegahan Tuberkulosis. 2024 [cited 2025 Jul 14].
6. Aceh Dinkes. Aceh catat penderita tuberkulosis di Aceh capai 12.656 kasus. 2025 [cited 2025 Jul 14].
7. Pemerintah Provinsi Aceh. Perkiraan Dinkes, TBC di Aceh 21 128 Kasus. Banda Aceh: Pemerintah Provinsi Aceh; 21 Nov 2023 [cited 2025 Aug 13].
8. Kemenkes RI. Petunjuk Teknis Manajemen dan tatalaksana TB Anak. Ministry of Health of the Republic of Indonesia. 2016.
9. Gafar F, Fitria N, Wilffert B. *Antituberculosis Drug-induced Liver Injury in Children*. *Pediatric Infect Dis J*. 2019;38(1):50–3.
10. World Health Organization. WHO. 2024 [cited 2025 Jul 14]. *Inclusion for every child: reaching every child affected by tuberculosis*.
11. Prasad R, Singh A, Gupta N. *Adverse drug reactions in tuberculosis and management*. *Indian J Tuberc*. 2019;66(4):520-532.
12. World Health Organization. *Global Tuberculosis Report 2021: Supplementary Material. Global tuberculosis report 2021: supplementary material*. 2021.
13. Setiati S, Alwi I, Sudoyo AW. *Buku Ajar Ilmu Penyakit Dalam*. InternaPublishing. 2014. 1-4168.
14. Aceh Dinkes. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Kemenkes RI. 2023;1–139.
15. Kemenkes RI. *Profil Kesehatan Indonesia Tahun 2020*. Jakarta: Kementerian Kesehatan RI; 2021.
16. PDPI. *Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Vol. 001, Perhimpunan Dokter Paru Indonesia. 2021. 1–78.
17. Tobin EH, Tristram D. *Tuberculosis overview*. *Treasure Island (FL): StatPearls Publishing*; 2025 Jan– [cited 2025 Aug 8].
18. Mulyadi, Fitrika Y. *Correlation between Tuberculosis with HIV/AIDS*. *Idea Nursing J*. 2020;II(2):162–8.
19. Barreto ML, Pereira SM, Ferreira AA. BCG vaccine: efficacy and indications for vaccination and revaccination. *Paediatr Respir Rev*. 2022;44:24-31.
20. Zhou Y, Zhu L, Li W, Liu J, Peng J, Wang X, et al. The protective effect

- of BCG vaccination on children: A retrospective study in China. *Vaccine*. 2022;40(4):607-614.
21. Riyanto A. Hubungan Kontak Erat Dan Kapasitas Rumah Dengan Terjadinya Tuberkulosis Paru Di Cimahi Selatan. *Hearty*. 2021;9(2):86.
 22. Rosalind L Smyth . *ADRIC: Adverse Drug Reactions In Children– a programme of research using mixed methods*. National Institute for Health Research. 2014.
 23. Laxmeshwar C, Stewart AG, Dalal A, Kalon S, Das M, Kumar AMV, et al. *Multidrug-resistant tuberculosis management in resource-limited settings*. Médecins Sans Frontières Access Campaign; 2019.
 24. Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R, et al. *Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children*. *BMC Infect Dis*. 2015;15:126.
 25. McIlleron H, Gous AG, Donald PR, et al. *Treating children with tuberculosis—using pharmacometrics to do better*. *Br J Clin Pharmacol*. 2022;88(5):1921–1934.
 26. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. *Factors and mechanisms for pharmacokinetic differences between pediatric population and adults*. *Pharmaceutics*. 2011;3(1):53–72.
 27. Chung SJ, Byeon SJ, Choi JH. *Analysis of adverse drug reactions to first-line anti-tuberculosis drugs using the Korea Adverse Event Reporting System*. *J Korean Med Sci*. 2022;37(16):128.
 28. Laghari M, Talpur BA, Syed Sulaiman SA, Khan AH, et al. *Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis*. *Int J Mycobacteriol*. 2020;9(3):281–8.
 29. Li Y, Zhu Y, Zhong Q, Zhang X, et al. *Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis*. *Pediatr Infect Dis J*. 2017;36(8):720–5.
 30. World Health Organization. *Guidance for national tuberculosis programmes on the management of tuberculosis in children*. 2nd ed. Geneva: World Health Organization; 2014. Chapter 4, Treatment of TB in children.
 31. Shah I, Jadhao N, Mali N, Deshpande S, et al. *Pharmacokinetics of isoniazid in Indian children with tuberculosis on daily treatment*. *Int J Tuberc Lung Dis*. 2019;23(1):52–7.
 32. Khairunnisa SA, Puspitasari IM. *Review: efek samping obat antituberkulosis oral lini pertama pada anak*. *Maj Ilmu Kefarmasian*. 2021;21(2):197–205.
 33. Sadanshiv M, George AA, Mishra AK, Kuriakose CK. *Rifampicin induced immune allergic reaction*. *Trop Doct*. 2018;48(2):156–9.
 34. Levy M, Rigaudière F, de Lauzanne A, Koehl B, et al. *Ethambutol-related impaired visual function in children less than 5 years of age treated for a mycobacterial infection: diagnosis and evolution*. *Pediatr Infect Dis J*. 2015;34(4):346–50.
 35. *Systematic review of age brackets in pediatric emergency medicine literature and the development of a universal age classification for*

- pediatric emergency patients (MACS). BMC Emerg Med.* 2023;23:51.
36. Ramachandran G, Kumar AK, Swaminathan S. *Pharmacokinetics of anti-tuberculosis drugs in children.* Indian J Pediatr. 2011;78(4):435–42.
 37. Ruslami R, Gafar F, Yunivita V, Parwati I, et al. *Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.* Arch Dis Child. 2022;107(1):70–7.
 38. Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, et al. *Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial.* J Antimicrob Chemother. 2021;76(12):3237–46.
 39. Marais BJ, Gie RP, Schaaf HS, Hesselning AC, et al. *The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.* Int J Tuberc Lung Dis. 2004;8(4):392–402.
 40. Horton KC, MacPherson P, Houben RM, White RG, et al. *Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis.* PLoS Med. 2016;13(9):e1002119.
 41. Klein SL, Flanagan KL. *Sex differences in immune responses.* Nat Rev Immunol. 2016;16(10):626–38.
 42. Soldin OP, Mattison DR. *Sex differences in pharmacokinetics and pharmacodynamics.* Clin Pharmacokinet. 2009;48(3):143–57.
 43. Cegielski JP, McMurray DN. *The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals.* Int J Tuberc Lung Dis. 2004;8(3):286–98.
 44. Bhargava A, Benedetti A, Oxlade O, Pai M, et al. *Undernutrition and the incidence of tuberculosis in India: national and subnational estimates of the population-attributable fraction related to undernutrition.* Natl Med J India. 2014;27(3):128–33.
 45. NCD Risk Factor Collaboration (NCD-RisC). *Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults.* Lancet. 2017;390(10113):2627–42.
 46. Han PY, Duffull SB, Kirkpatrick CM, Green B. *Dosing in obesity: a simple solution to a big problem.* Clin Pharmacol Ther. 2007;82(5):505–8.
 47. World Health Organization. *WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Web annex 5. Overview of consolidated WHO recommendations.* Geneva: World Health Organization; 2022.
 48. Alffenaar JWC, de Steenwinkel JEM, Diacon AH, Simonsson USH, et al. *Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: an evaluation of in vitro, in vivo methodologies and human studies.* Front Pharmacol. 2022;13:1063453.
 49. Chang KC, Leung CC, Yew WW, Lau TY. *Hepatotoxicity of pyrazinamide: cohort and case-control analyses.* Am J Respir Crit Care Med. 2008;177(12):1391–6.

50. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, et al. *Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children*. Clin Infect Dis. 2017;64(2):111–5.
51. Perez-Velez CM, Marais BJ. *Tuberculosis in children*. N Engl J Med. 2012;367(4):348–61.
52. Trunz BB, Fine P, Dye C. *Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness*. Lancet. 2006;367(9517):1173–80.
53. Mangtani P, Abubakar I, Ariti C, Beynon R, et al. *Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials*. Clin Infect Dis. 2014;58(4):470–80.
54. Andersen P, Doherty TM. *The success and failure of BCG—implications for a novel tuberculosis vaccine*. Nat Rev Microbiol. 2005;3(8):656–62.
55. Nahid P, Dorman SE, Alipanah N, Barry PM, et al. *Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis*. Clin Infect Dis. 2016;63(7):853–67.
56. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, et al. *Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis*. PLoS Med. 2018;15(7):e1002591.
57. Yee D, Valiquette C, Pelletier M, Parisien I, et al. *Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis*. Am J Respir Crit Care Med. 2003;167(11):1472–7.
58. Leibold JE. *The ocular toxicity of ethambutol and its relation to dose*. Ann N Y Acad Sci. 1966;135(2):904–9.
59. Rybak LP, Ramkumar V. *Ototoxicity*. Kidney Int. 2007;72(8):931–5.
60. Donald PR, Schaaf HS. *Old and new drugs for the treatment of tuberculosis in children*. Paediatr Respir Rev. 2007;8(2):134–41.